1 completed, 1 recruiting, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Gamunex-C: new trials by email Literature Review of Gamunex-C trials Research Report on Gamunex-C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 3 | Recruiting | Grifols Therapeutics LLC | 40 | 2026-04-02 | 2026-11-10 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Gamunex-C, IVIG-PEG - Primary Immunodeficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 33 | 2020-09-02 | 2023-06-05 |
| IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy Intravenous Immunoglobulin, Placebos, Normal Saline - Autoimmune Epilepsy | Phase 3 | Terminated | Mayo Clinic | 17 | 2016-02-01 | 2019-12-30 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Primary Immunodeficiency Diseases (1)
Grifols Therapeutics LLC (2) · Mayo Clinic (1)
United States (3) · Czechia (1) · Poland (1) · Romania (1)